CSL’s Sequiris to build next-generation AU influenza vaccine manufacturing facility

Nov 16, 2020

CSL’s Sequiris announced it will build a next-generation $800 million influenza vaccine manufacturing facility in Australia. The facility is expected to be operational by mid-2026 and will be the only cell-based influenza vaccine manufacturing facility in the Southern Hemisphere.

Print Page Mail Article